Pediatric Urology Academy

The classic androgen pathway is not the whole story.

A fetus can generate androgen effect through an alternative biochemical route that bypasses testosterone as the obligatory intermediate.

In this episode of Pediatric Urology Academy, we examine the human backdoor androgen pathway and why it matters when genotype, serum hormones, and genital phenotype do not seem to fit neatly together.

We explore:

• how fetal tissues can reach DHT through more than one biochemical route
• why serum testosterone does not fully represent androgen exposure at the target tissue
• the role of androsterone in human fetal backdoor androgen biology
• how AKR1C2 and AKR1C4 defects can produce 46,XY undervirilization
• why POR deficiency can produce both 46,XY undervirilization and 46,XX virilization
• how excess steroid precursors can be redirected through alternative androgen pathways
• why placenta, adrenal, liver, testis, and peripheral tissues should be viewed as a distributed fetal steroidogenic system
• when urinary steroid profiling and molecular testing become particularly useful
• why the backdoor pathway should be used to localize biology, not as a catch-all diagnosis

The central framework:

The classic pathway is the main road.

The backdoor pathway is the side road.

External genital development reflects the total androgen signal that reached the target during the critical developmental window.

Season 6 — Differences of Sex Development: Reconstruct the Biology

Hosted by Amin Afrasiabi, MD
Pediatric Urology Academy

A 46,XY child can have testes, no uterus, preserved Wolffian structures—and markedly undervirilized external genitalia.

The testosterone may even be normal.

The missing signal is DHT.

In this episode of Pediatric Urology Academy, we examine SRD5A2 deficiency as a disorder of tissue-specific androgen amplification rather than simply “low androgen.”

We explore:

• why testosterone and DHT are not biologically interchangeable
• how Wolffian structures can masculinize while external genital virilization remains incomplete
• why SRD5A2 acts as a local androgen amplifier during fetal development
• how the testosterone-to-DHT ratio helps localize the defect, but cannot reliably confirm or exclude it
• why hCG stimulation and urinary steroid profiling can add diagnostic information
• how SRD5A2 deficiency differs from HSD17B3 deficiency and complete androgen insensitivity
• why substantial virilization may occur at puberty despite severe fetal undervirilization
• why puberty cannot recreate developmental windows that were missed in fetal life
• what current evidence suggests about fertility, gonadal preservation, and tumor risk

The central framework:

Testosterone delivers the androgen signal.

DHT amplifies it in selected tissues.

Season 6 — Differences of Sex Development: Reconstruct the Biology

Hosted by Amin Afrasiabi, MD
Pediatric Urology Academy

A 46,XY child can have testes, no uterus, and markedly undervirilized external genitalia—then virilize substantially at puberty.

The explanation lies inside the steroid pathway.

In this episode of Pediatric Urology Academy, we examine HSD17B3 deficiency through a precursor–product framework: androstenedione is produced, but its conversion to testosterone is impaired.

We explore:

• why preserved Müllerian regression does not prove normal testosterone synthesis
• how androstenedione identifies the biochemical bottleneck
• why the testosterone-to-androstenedione ratio is useful but not diagnostic
• how hCG stimulation and mini-puberty can expose the defect
• why puberty can partially bypass the fetal metabolic block
• how HSD17B3 deficiency differs from complete androgen insensitivity and SRD5A2 deficiency
• why genotype does not perfectly predict phenotype
• the evolving controversy around gonadal preservation, tumor risk, puberty suppression, and fertility

The central framework:

Do not measure only the final hormone.

Follow the substrate.

Follow the product.

Find where the pathway stopped.

Season 6 — Differences of Sex Development: Reconstruct the Biology

Hosted by Amin Afrasiabi, MD
Pediatric Urology Academy

The testes are present.

Müllerian structures are absent.

Yet the external genitalia may be profoundly undervirilized.

That combination localizes the problem.

In this episode of Pediatric Urology Academy, we examine Leydig cell hypoplasia through one of the most useful frameworks in 46,XY DSD: a single receptor is challenged during two different developmental eras.

Placental hCG tests the fetal Leydig cell.

Pituitary LH tests it again at puberty.

We explore:

• how LHCGR dysfunction disrupts fetal testosterone production while preserving Sertoli-cell AMH function
• why absent Müllerian structures can coexist with severe undervirilization
• how Leydig cell hypoplasia differs from gonadal dysgenesis and androgen insensitivity
• why high LH with low testosterone represents a failed Leydig response rather than simply “hypogonadism”
• how hCG stimulation testing should—and should not—be interpreted
• why residual LHCGR activity produces a continuum of phenotypes
• how fetal genital phenotype and pubertal endocrine function interrogate the same receptor under different physiological demands
• where molecular testing adds information beyond endocrine testing

The central framework:

One receptor.
Two developmental eras.

hCG writes the fetal phenotype.

LH reveals what remains at puberty.

Season 6 — Differences of Sex Development: Reconstruct the Biology

Hosted by Amin Afrasiabi, MD
Pediatric Urology Academy

A boy can have male-typical external genitalia, no Müllerian structures, a vas deferens—and no testis.

That is not a contradiction.

It is a developmental timeline.

In this episode of Pediatric Urology Academy, we examine testicular regression syndrome as a problem of reconstructing when a previously functioning fetal testis was lost.

We explore:

• how Müllerian anatomy, Wolffian structures, and external virilization act as developmental timestamps
• why testicular regression differs fundamentally from true agenesis
• how intrauterine torsion or vascular injury may leave a fibrotic nubbin
• how AMH, inhibin B, and gonadotropins help evaluate bilateral nonpalpable testes
• why contralateral compensatory hypertrophy is a clue, not proof
• how operative anatomy distinguishes blind-ending vessels, vanishing testis, and distal remnants
• why a testicular nubbin is biologically different from a dysgenetic gonad
• why hypoplasia, hypotrophy, atrophy, and regression should not be used interchangeably

The central framework is simple:

Phenotype is a developmental flight recorder.

Read the Müllerian structures.

Read the Wolffian structures.

Read the genital phenotype.

Then reconstruct when the testis disappeared.

Season 6 — Differences of Sex Development: Reconstruct the Biology

Hosted by Amin Afrasiabi, MD
Pediatric Urology Academy

A 46,XY child can have female-typical external genitalia and streak gonads.

Another can have hypospadias, partial Müllerian regression, a palpable gonad, and spontaneous virilization at puberty.

The difference is not simply “more or less testosterone.”

It is how much functional testicular tissue was actually built.

In this episode of Pediatric Urology Academy, we reconstruct complete and partial gonadal dysgenesis as disorders of testicular development rather than isolated endocrine failure.

We examine:

• why gonadal dysgenesis differs fundamentally from androgen synthesis defects and androgen insensitivity
• how Sertoli, Leydig, and germ-cell function can survive to different degrees
• why fetal testicular failure does not always predict pubertal endocrine failure
• how genes including SRY, SOX9, NR5A1, MAP3K1, and WT1 fit into the developmental framework
• why dysgenetic gonads require careful assessment of germ-cell tumor risk
• why imaging, tumor markers, and limited biopsy cannot completely eliminate uncertainty
• how to balance endocrine value, fertility potential, gonadal position, histology, and oncologic risk

The central question is not:

“Is there a testis?”

It is:

“How much testis was ever built?”

Season 6 — Differences of Sex Development: Reconstruct the Biology

Hosted by Amin Afrasiabi, MD
Pediatric Urology Academy

A normally virilized boy can have testes, vasa deferentia—and a uterus.

That contradiction is the key to persistent Müllerian duct syndrome.

In this episode of Pediatric Urology Academy, we reconstruct PMDS as a selective failure of the AMH pathway rather than global testicular failure.

We examine:

• how AMH and AMHR2 defects produce similar anatomy through different mechanisms
• why normal male external genitalia do not prove Müllerian regression
• how serum AMH can help localize the defect
• why cryptorchidism and transverse testicular ectopia are important clinical clues
• how Müllerian remnants complicate orchidopexy and vas preservation
• why complete excision is not always the safest surgical objective
• what the evidence actually shows about fertility and malignancy risk

The operative principle is simple:

Preserve useful biology before pursuing anatomical perfection.

Season 6 — Differences of Sex Development: Reconstruct the Biology

Hosted by Amin Afrasiabi, MD
Pediatric Urology Academy

A testis is not one biological unit.

Sertoli cells, Leydig cells, and germ cells perform different jobs, follow different developmental timelines, and can fail independently.

In this episode of Pediatric Urology Academy, we examine how one gonad can preserve Müllerian regression, show impaired androgen-related function, and still contain germ cells with separate implications for fertility and tumor risk.

The central clinical lesson is that no single hormone can certify “normal testicular function.”

We explore:

• why Müllerian regression is a historical marker of fetal Sertoli-AMH activity, not proof of present gonadal health
• why normal testosterone does not exclude Sertoli-cell dysfunction
• how mini-puberty can reveal discordant testicular compartments
• why AMH and inhibin B are not direct measures of germ-cell content
• why endocrine silence does not eliminate germ-cell or tumor risk
• how to separate endocrine value, fertility potential, and oncologic risk when making gonadal decisions

The practical framework is simple:

One gonad.
Three compartments.
Three biological histories.

Season 6 — Differences of Sex Development: Reconstruct the Biology

Hosted by Amin Afrasiabi, MD
Pediatric Urology Academy

SRY is present.

So why can a 46,XY gonad still become dysgenetic?

In this episode of Pediatric Urology Academy, we move beyond the textbook idea of SRY as a simple male switch.

Gonadal determination is better understood as a time-sensitive developmental competition.

SRY initiates the testicular program through SOX9, while pathways including WNT4, RSPO1, beta-catenin, and FOXL2 support ovarian differentiation.

The critical question is not simply whether SRY exists.

It is whether the developing gonad crosses the testicular commitment threshold early enough for that program to become self-sustaining.

We explore:

SRY and SOX9 as a developmental network.

Why two 46,XY patients with intact SRY can have very different gonadal phenotypes.

How 46,XX testicular development can occur without SRY.

Why SOX9 regulatory DNA matters as much as coding sequence.

The remarkable phenotypic variability of NR5A1-related DSD.

How MAP3K1 can shift the balance between testicular and ovarian pathways.

And why gene dosage, regulatory variants, mosaicism, and developmental timing matter when sequencing does not explain the phenotype.

The clinical principle is simple:

The presence of SRY does not prove the presence of a normally functioning testis.

Pediatric Urology Academy
Hosted by Amin Afrasiabi, MD

Advanced education for clinicians and trainees in pediatric urology.

In differences of sex development, phenotype should not be treated as the diagnosis.

It is a record of development.

In this opening episode of Season 6, Pediatric Urology Academy builds a physiology-first framework for interpreting 46,XY DSD.

The discussion follows five developmental checkpoints:

Chromosomal sex.
Gonadal determination.
Sertoli-cell function.
Leydig-cell function.
Target-tissue androgen response.

Why does a uterus matter in a 46,XY infant?

What does preservation of the vas deferens tell us about fetal testosterone exposure?

Why can Müllerian, Wolffian, hormonal, and external-genital findings appear contradictory?

And why may that discordance be the most diagnostically valuable finding?

The central principle is simple:

Before assigning a syndrome name, identify which developmental signal failed, when it failed, and which biological functions remain intact.

Pediatric Urology Academy
Hosted by Amin Afrasiabi, MD

Educational content for clinicians and trainees. It does not replace individualized clinical assessment or multidisciplinary DSD care.